Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.77 |
| ▸ | RAF1 | P04049 | 14/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.50 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958787 | 0.89 | MAP2K1 (0.86) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL964469 | 0.88 | MAP2K1 (0.84) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL963828 | 0.88 | MAP2K1 (0.84) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL959233 | 0.87 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL961095 | 0.86 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL960417 | 0.86 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL958665 | 0.86 | MAP2K1 (0.79) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL964533 | 0.82 | MAP2K1 (0.75) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL960444 | 0.81 | MAP2K1 (0.73) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL962144 | 0.81 | MAP2K1 (0.88) | MAP2K1RAF1CYP2C9CYP3A4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | MAP2K1 1179/4885RAF1 1656/4885CYP2C9 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.